LifeVantage (NASDAQ:LFVN) Coverage Initiated by Analysts at Lake Street Capital

Analysts at Lake Street Capital began coverage on shares of LifeVantage (NASDAQ:LFVN) in a report released on Thursday,Benzinga reports. The firm set a “buy” rating and a $26.00 price target on the stock. Lake Street Capital’s target price points to a potential upside of 69.38% from the stock’s previous close.

LifeVantage Trading Down 7.5 %

LFVN opened at $15.35 on Thursday. The firm’s 50 day simple moving average is $13.77 and its two-hundred day simple moving average is $10.19. The company has a market capitalization of $192.26 million, a PE ratio of 47.97 and a beta of 0.87. LifeVantage has a 1-year low of $5.22 and a 1-year high of $17.49.

LifeVantage (NASDAQ:LFVN) last released its earnings results on Tuesday, October 29th. The company reported $0.15 earnings per share for the quarter, meeting the consensus estimate of $0.15. The company had revenue of $47.21 million for the quarter. LifeVantage had a return on equity of 29.24% and a net margin of 2.11%.

Institutional Investors Weigh In On LifeVantage

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Hantz Financial Services Inc. purchased a new position in shares of LifeVantage in the second quarter worth $91,000. Ritholtz Wealth Management lifted its stake in LifeVantage by 62.0% in the 3rd quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock worth $346,000 after purchasing an additional 10,974 shares in the last quarter. Barclays PLC boosted its holdings in shares of LifeVantage by 38.2% during the 3rd quarter. Barclays PLC now owns 41,966 shares of the company’s stock valued at $507,000 after purchasing an additional 11,608 shares during the last quarter. HighTower Advisors LLC bought a new position in shares of LifeVantage during the 3rd quarter valued at about $638,000. Finally, Capital Management Corp VA purchased a new position in shares of LifeVantage during the third quarter valued at about $5,073,000. 35.32% of the stock is owned by institutional investors.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.